앱클론

174900KOSDAQ의료용품 및 기타 의약 관련제품 제조업

57.8 / 100

Reference Date: 2026-07-24

Financial Score18.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 28.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Appclone is a biotech company specializing in the development of monoclonal antibody-based pharmaceuticals. It focuses on creating 'Biosynergy' drugs that enhance efficacy when combined with existing medications and 'Biounique' antibodies with distinct mechanisms of action for monotherapy. The company also leverages its 'Affibody' technology and human antibody library to develop innovative treatment solutions.

Number of Employees

66people

Average Salary

57.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.184.0Point

PBR

6.85Industry Average 1.090.0Point

6.3x industry avg (risky)

ROE

-39.86Industry Average -4.893.5Point

8.2x industry avg (excellent)

Debt Ratio

1.58Industry Average 6.868.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼23.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -45.9% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
앱클론, 유펜과 공동개발 ‘CD30 CAR-T’ 美 특허 획득
앱클론이 미국 펜실베이니아대와 공동으로 악성 림프종 치료에 효과적인 새로운 CAR-T 치료제 관련 특허를 획득하여 기술 경쟁력을 강화했습니다.
Positive
앱클론, 튀르키예서 ‘혈액암·고형암’ CAR-T 개발 협력 나서
앱클론이 튀르키예와의 협력으로 CAR-T 치료제 개발 임상 가속화에 성공, 미래 성장 가능성 확대.
Positive
앱클론, 튀르키예 TCT와 'AT101' 임상 가속화 및 차세대 CA...
앱클론이 튀르키예 TCT와의 협력으로 임상 진행 가속화를 이끌어내며 긍정적인 시장 반응을 얻고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 20,750Won52-week high 89,10052-week low 9,890

1-month return0.0Point

1m -28.45% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 3Neutral 0Negative 0

Positive[기재정정]단일판매ㆍ공급계약체결2026-07-22
Positive[기재정정]단일판매ㆍ공급계약체결2026-07-07
Positive[기재정정]단일판매ㆍ공급계약체결(자율공시)2026-06-30